Abstract
Annual Review of Pharmacology and Toxicology
Vol. 42:
55-80
(Volume publication date April 2002)
(doi:10.1146/annurev.pharmtox.42.082301.164620)
COX-2: A Target for Colon Cancer Prevention Lawrence J. Marnett1 and Raymond N. DuBois2 A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Center in Molecular Toxicology, Departments of Biochemistry 1, Chemistry 1, Vanderbilt University School of Medicine, Nashville, Tennessee 37232; e-mail: marnett@toxicology.mc.vanderbilt.edu A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Center in Molecular Toxicology, Departments of Medicine 2, and Cell Biology 2, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232; e-mail: raymond.dubois@mcmail.vanderbilt.edu ▪ Abstract Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention. Most recent citing papers (via CrossRef)Use of Nonsteroidal Antiinflammatory Drugs and Distal Large Bowel Cancer in Whites and African Americans American Journal of Epidemiology (2008) Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells Digestive Diseases and Sciences (2008) Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP Oncogene 27(18):2656-2660 (2008) 2, 3-Diaryl-5-ethylsulfanylmethyltetrahydrofurans as a new class of COX-2 inhibitors and cytotoxic agents Organic & Biomolecular Chemistry 6(15):2706 (2008) The 15-lipoxygenase-1 expression may enhance the sensitivity to non-steroidal anti-inflammatory drug-induced apoptosis in colorectal cancers from patients who are treated with the compounds Journal of Gastroenterology and Hepatology 22(12):2324-2329 (2008)
|
|
|
RSS
Chain of Reviews
